NOVANTA INC — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Novanta reported Q2 2026 GAAP revenue of $265.8M (10.3% YoY growth), with organic growth of 9.3%. GAAP net income was $12.5M ($0.30 diluted EPS); adjusted EBITDA was $60.7M (+16.4% YoY) with 22.8% margin. The company closed the Riverpoint Medical acquisition (amount undisclosed in filing), which doubles recurring medical consumables business to ~25% of sales and increases medical end-market exposure to ~60%. Full-year 2026 guidance raised: revenue $1,130M–$1,140M (>15% growth), Adjusted EBITDA $273M–$278M (>24% growth), Adjusted Diluted EPS $3.68–$3.74 (>12% growth), all incorporating Riverpoint contribution.
Why this rating
Solid operational quarter with strong growth and margin expansion, plus strategic acquisition doubling key segment. Modest relative to $3.5B market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.